Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Capital Expenditures (2019 - 2025)

Pulmonx (LUNG) has disclosed Capital Expenditures for 7 consecutive years, with -$63000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures rose 90.68% to -$63000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 310.47% increase, with the full-year FY2024 number at $1.4 million, up 1227.52% from a year prior.
  • Capital Expenditures was -$63000.0 for Q3 2025 at Pulmonx, down from $66000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.2 million in Q4 2024 to a low of -$717000.0 in Q4 2022.
  • A 5-year average of $135631.6 and a median of $66000.0 in 2025 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: tumbled 214.38% in 2021, then surged 4415.79% in 2024.
  • Pulmonx's Capital Expenditures stood at -$481000.0 in 2021, then tumbled by 49.06% to -$717000.0 in 2022, then soared by 107.25% to $52000.0 in 2023, then skyrocketed by 2213.46% to $1.2 million in 2024, then tumbled by 105.24% to -$63000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Capital Expenditures are -$63000.0 (Q3 2025), $66000.0 (Q2 2025), and $9000.0 (Q1 2025).